American Society of Clinical Oncology (ASCO)

Findings from KEYNOTE-598 detected no difference in health-related quality of life or time to true deterioration in lung cancer symptoms comparing treatment with pembrolizumab + ipilimumab versus pembrolizumab + placebo in patients with previously untreated metastatic non–small-cell lung cancer (NSCLC) with PD-L1 tumor proportion score ≥50%. Read More ›

Findings of the prospective community-based observational NILE study support the use of cfDNA to identify actionable genomic alterations in newly diagnosed patients with advanced lung adenocarcinoma. Read More ›

Sotorasib, an oral KRAS inhibitor, was effective across specified subgroups of patients with KRAS G12C–mutated non–small-cell lung cancer (NSCLC). Read More ›

The cost burden of adjunctive osimertinib therapy is higher than the observed clinical benefit for patients with resected EGFR-positive non–small-cell lung cancer (NSCLC). Read More ›

The ACCURE intervention using a combination of real-time electronic health record monitoring, nurse navigation, and race-based feedback significantly improved delivery of timely lung cancer surgery and markedly reduced racial disparities for patients with early-stage lung cancer. Read More ›

The combination of EGFR-tyrosine kinase inhibitor (TKI) and MET-TKI therapy improves clinical outcomes in patients who developed MET amplification after prior EGFR-TKI therapy in EGFR-mutated non–small-cell lung cancer (NSCLC). Read More ›

First-line use of nivolumab + ipilimumab in patients with advanced non–small-cell lung cancer (NSCLC) offers durable survival relative to chemotherapy alone with ≥2 years of follow-up. Read More ›

Findings of a global ancestry analysis confirm that African ancestry is associated with worse survival outcomes among patients with lung adenocarcinoma. Read More ›

Comprehensive biomarker testing and clinical trial participation rates were significantly lower for black patients in the United States compared with white patients with advanced non–small-cell lung cancer (NSCLC). Read More ›

Nivolumab in combination with ipilimumab delivers durable, long-term survival benefit versus chemotherapy in patients with advanced non–small-cell lung cancer (NSCLC) regardless of PD-L1 expression with 4 years of follow-up. Read More ›